KRAS, BRAF mutations, and HER2 expression in patients operated for pancreatic adenocarcinomas.
2010
4043 Background: The results of cytostatic treatment in pancreatic ductal adenocarcinomas (PDAC) are still disappointing. Standard treatment is still gemcitabine, monotherapy or in combinations. St...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI